DI NUNNO, VINCENZO
 Distribuzione geografica
Continente #
NA - Nord America 940
EU - Europa 422
AS - Asia 251
AF - Africa 38
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 1657
Nazione #
US - Stati Uniti d'America 936
GB - Regno Unito 156
VN - Vietnam 132
SE - Svezia 110
CN - Cina 67
IT - Italia 43
DE - Germania 41
IN - India 39
TG - Togo 26
RU - Federazione Russa 24
FR - Francia 19
ZA - Sudafrica 12
EE - Estonia 11
UA - Ucraina 7
BE - Belgio 6
JP - Giappone 6
AU - Australia 3
MY - Malesia 2
NI - Nicaragua 2
NL - Olanda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
CA - Canada 1
EU - Europa 1
IE - Irlanda 1
IR - Iran 1
LB - Libano 1
MX - Messico 1
NO - Norvegia 1
RO - Romania 1
SA - Arabia Saudita 1
SG - Singapore 1
UZ - Uzbekistan 1
Totale 1657
Città #
Fairfield 151
Southend 145
Ashburn 75
Princeton 74
Seattle 74
Houston 71
Woodbridge 67
Chandler 65
Dong Ket 65
Wilmington 59
Cambridge 52
Ann Arbor 50
Berlin 26
Lomé 26
Westminster 15
Beijing 14
Redwood City 12
Bologna 9
Des Moines 9
Nanjing 9
Redmond 9
San Diego 9
Falls Church 8
Glasgow 6
Shenyang 6
Brussels 4
Hebei 4
Jinan 4
Kumar 4
Tianjin 4
Torino 4
Changsha 3
Chicago 3
Hangzhou 3
Kuban 3
Milan 3
Sacramento 3
Zhengzhou 3
Canberra 2
Clearwater 2
Costa Mesa 2
Dearborn 2
Frankfurt Am Main 2
Fremont 2
Groningen 2
Haikou 2
Kuala Lumpur 2
Managua 2
Nanchang 2
Ningbo 2
Norwalk 2
Padova 2
Parabiago 2
Saint Petersburg 2
San Francisco 2
Altamira 1
Andover 1
Braine-l'alleud 1
Buenos Aires 1
Delhi 1
Dublin 1
Florence 1
Guangzhou 1
Jiaxing 1
Kiev 1
Kunming 1
Lanzhou 1
Las Vegas 1
Leawood 1
Medford 1
Melbourne 1
Monmouth Junction 1
Oslo 1
Phoenix 1
Ravenna 1
Riyadh 1
Rome 1
San Giovanni In Marignano 1
Shenzhen 1
Singapore 1
Taizhou 1
Tallinn 1
Toronto 1
Vicenza 1
Villafranca Di Verona 1
Totale 1215
Nome #
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. 130
Circulating tumor cells in genitourinary tumors 122
Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. 115
Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors 99
Cabozantinib-related cardiotoxicity: a prospective analysis in a "real world" cohort of metastatic renal cell carcinoma patients 97
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 80
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. 80
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience 75
Immune checkpoint inhibitors for metastatic bladder cancer 74
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis 73
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. 67
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. 65
The human microbiota and prostate cancer: Friend or foe? 64
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma 55
Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.09.008 52
Immortal time bias question in the association between toxicity and outcome of immune checkpoint inhibitors 52
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients 40
Rare Primary Central Nervous System Tumors in Adults: An Overview 37
The clinical and prognostic role of ALK in glioblastoma 34
Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis. 26
IDH1105GGT single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas 25
Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study 24
Idh1 non-canonical mutations and survival in patients with glioma 22
Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study 22
Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review 22
Glioblastoma: Emerging treatments and novel trial designs 22
Discovering the molecular landscape of meningioma: The struggle to find new therapeutic targets 22
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study 22
Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer? 20
Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem 20
Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: An unassessed issue 18
Immune-checkpoint inhibitors in pituitary malignancies 17
Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases 16
IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment 16
Meningioma: Not always a benign tumor. A review of advances in the treatment of meningiomas 11
Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light 10
Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. 9
Totale 1755
Categoria #
all - tutte 2842
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2842


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201815 0000 00 01 00410
2018/201956 4751 05 16 411012
2019/2020472 5411026 5141 6069 68432920
2020/2021338 4612293 214 66 35147155
2021/2022623 12181524 5322 962 596119494
2022/2023249 91107429 00 00 0000
Totale 1755